Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus

Vaccine

Volumn 29, Issue 9, 2011, Pages 1791-1800

  Satoh, Ryoichi ^a   Furukawa, Tomoko ^a   Kotake, Masako ^a   Takano, Tomomi ^a   Motokawa, Kenji ^b   Gemma, Tsuyoshi ^b   Watanabe, Rie ^b   Arai, Setsuo ^b   Hohdatsu, Tsutomu ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Coronavirus; Epitope; FIP; Linear immunodominant antibody binding; Th1 epitope

Indexed keywords

EPITOPE; GAMMA INTERFERON; NUCLEOCAPSID PROTEIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CAT; CELL ISOLATION; CELL SCREENING; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONAVIRUS; CORONAVIRUS INFECTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOREACTIVITY; LEUKOCYTE CULTURE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; TH1 CELL; VIRUS STRAIN;

EID: 79952695016     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.106     Document Type: Article

References (47)

1. Hohdatsu T, Okada S, Koyama H. Characterization of monoclonal antibodies against feline infectious peritonitis virus type II and antigenic relationship between feline, porcine, and canine coronaviruses. ArchVirol 1991;117:85-95.
2. Motokawa K, Hohdatsu T, Aizawa C, Koyama H, Hashimoto H. Molecular cloning and sequence determination of the peplomer protein gene of feline infectious peritonitis virus type I. Arch Virol 1995;140:469-80.
3. Motokawa K, Hohdatsu T, Hashimoto H, Koyama H. Comparison of the amino acid sequence and phylogenetic analysis of the peplomer, integral membrane and nucleocapsid proteins of feline, canine and porcine coronaviruses. Microbiol Immunol 1996;40:425-33.
4. Woods RD, Pedersen NC. Cross-protection studies between feline infectious peritonitis and porcine transmissible gastroenteritis viruses. Vet Microbiol 1979;4:11-6.
5. Pedersen NC, Boyle JF, Floyd K, Fudge A, Barker J. An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res 1981;42:368-77.
6. Pedersen NC, Black JW. Attempted immunization of cats against feline infectious peritonitis, using avirulent live virus or sublethal amounts of virulent virus. Am J Vet Res 1983;44:229-34.
7. Pedersen NC, Evermann JF, Mckeirnan AJ, Ott RL. Pathogenicity studiesof feline coronavirus isolates 79-1146 and 79-1683. Am J Vet Res 1984;45:2580-5.
8. Barlough JE, Stoddart CA, Sorresso GP, Jacobson RH, Scott FW. Experimental inoculation of cats with canine coronavirus and subsequent challenge with feline infectious peritonitis virus. Lab Anim Sci 1984;34:592-7.
9. Stoddart CA, Barlough JE, Baldwin CA, Scott FW. Attempted immunisation of cats against feline infectious peritonitis using canine coronavirus. Res Vet Sci 1988;45:383-8.
10. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 2009;11:225-58.
11. Pedersen NC, Boyle JF. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 1980;41:868-76.
12. Weiss RC,Scott FW. Antibody-mediated enhancement of disease infeline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 1981;4:175-89.
13. Weiss RC, Cox NR. Delayed-type hypersensitivity skin response associated with feline infectious peritonitis in two cats. Res Vet Sci 1988;44:396-8.
14. Weiss RC, Cox NR. Evaluation of immunity to feline infectious peritonitis in cats with cutaneous viral-induced delayed hypersensitivity. Vet Immunol Immunopathol 1989;21:293-309.
15. Kiss I, Poland AM, Pedersen NC. Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD8. J Feline Med Surg 2004;6:89-97.
16. Gelain ME, Meli M, Paltrinieri S. Whole blood cytokine profiles in cats infected by feline coronavirus and healthy non-FCoV infected specific pathogen-free cats. J Feline Med Surg 2006;8:389-99.
17. Olsen CW. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 1993;36:1-37.
18. Bosch BJ, van der ZeeR, de Haan CA, Rottire PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003;77:8801-11.
19. Dimitrov DS. Virus entry molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004;2:109-22.
20. Corapi WV, Olsen CW, Scott FW. Mono clonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 1992;66:6695-705.
21. Corapi WV, Darteil RJ, Audonnet JC, Chappuis GE. Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement. J Virol 1995;69:2858-62.
22. Olsen CW, Corapi WV, Ngichabe CK, Baines JD, Scott FW. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 1992;66:956-65.
23. Hohdatsu T, Yamada H, Ishizuka Y, Koyama H. Enhancement and neutralization of feline infectious peritonitis virus infection in feline macrophages by neutralizing monoclonal antibodies recognizing different epitopes. Microbiol Immunol 1993;37:499-504.
24. Hohdatsu T, Yamada M, Tominaga R, Makino K, Kida K, Koyama H. Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J Vet Med Sci 1998;60:49-55.
25. Kida K, Hohdatsu T, Fujii K, Koyama H. Selection of antigenic variants of the S glycoprotein of feline infectious peritonitis virus and analysis of antigenic sites involved in neutralization. J Vet Med Sci 1999;61:935-8.
26. + T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 2004;104:200-6.
27. Wang YD, Sin WY, Xu GB, Yang HH, Wong TY, Pang XW, et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol 2004;78:5612-8.
28. + T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 2005;175:591-8.
29. Liu SJ, Leng CH, Lien SP, Chi HY, Huang CY, Lin CL, et al. Immunological characterizationsofthe nucleocapsid protein based SARS vaccine candidates. Vaccine 2006;24:3100-8.
30. Peng H, Yang LT, Wang LY, Li J, Huang J, Lu ZQ, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid proteininSARS-recovered patients. Virology 2006;351:466-75.
31. Tsao YP, Lin JY, Jan JT, Leng CH, Chu CC, Yang YC, et al. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006;344:63-71.
32. Yang LT, Peng H, Zhu ZL, Li G, Huang ZT, Zhao ZX, et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 2006;120:171-8.
33. Zhou M, Xu D, Li X, Li H, Shan M, Tang J, et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epi-topes. J Immunol 2006;177:2138-45.
34. Zhao J, Huang Q, Wang W, ZhangY, Lv P, Gao XM. Identification and characterization of dominant helper T-cell epitopes inthe nucleocapsid proteinof severe acute respiratory syndrome coronavirus. J Virol 2007;81:6079-88.
35. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, et al. Identification of immuno dominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004;173:4050-7.
36. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 2004;42:5309-14.
37. Satoh R, Kobayashi H, Takano T, Motokawa K, Kusuhara H, Hohdatsu T. Characterization of T helper (Th)1- and Th2-type immune responses caused by baculovirus-expressed protein derived from the S2 domain of feline infectious peritonitis virus,andexplorationoftheTh1 and Th2epitopesinamousemodel. Microbiol Immunol 2010;54:726-33.
38. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
39. + T cell response. J Immunol 2002;168:5455-64.
40. + T-cell differentiation in response to viruses. Nat Rev Immunol 2003;3:931-9.
41. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-45.
42. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005;174:1037-45.
43. Peng H, Yang LT, Li J, Lu ZQ, Wang LY, Koup RA, et al. Human memory T cell responses to SARS-CoV E protein. Microbes Infect 2006;8:2424-31.
44. Li T, Qiu Z, Han Y, Wang Z, Fan H, Lu W, et al. Rapid loss of both CD4+ and CD8+ T lymphocyte subsets during the acute phase of severe acute respiratory syndrome. Chin Med J 2003;116:985-7.
45. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, etal. Vaccination with cytotoxicTlymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
46. Stohlman SA, Bergmann C, Cua D, Wege H, van der Veen R. Location of antibody epitopes within the mouse hepatitis virus nucleocapsid protein. Virology 1994;202:146-53.
47. Collisson EW, Pei J, Dzielawa J, Seo SH. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev Comp Immunol 2000;24:187-200.